Riskpilot← Back to searchSign inGet full accessGenagon Therapeutics AB
ABIn liquidationOrg 5590164082Other research and experimental development on natural sciences and engineering · NACE 7219Est. 20150 employees
Revenue 2023
SEK 214K
+189% vs 2022
EBITDA margin
-74.3%
+98% vs 2022
Equity ratio
70.3%
Financial strength
Net profit 2023
SEK -164K
+98% vs 2022
| Revenue | SEK 214K | +189% |
| EBITDA | SEK -159K | +98% |
| Net profit | SEK -164K | +98% |
| Total assets | SEK 6,9M | +21% |
| Equity | SEK 4,8M | -3% |
| Employees | 0 | — |
Legal name
Genagon Therapeutics AB
Org number
5590164082
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
5 juni 2015
Share capital
SEK 204 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska bedriva utveckling och kommersialisering av läkemedel och medicintekniska produkter samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 35 | 74 | 214 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −14 839 | −5 211 | −8 739 | −9 821 | −159 |
| Depreciation & amort. | −5 | −5 | −4 | −6 | −5 |
| EBIT | −14 844 | −5 216 | −8 743 | −9 827 | −164 |
| Net financials | — | −1 | — | — | −1 |
| Profit before tax | −14 844 | −5 218 | −8 743 | −9 827 | −164 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −14 844 | −5 218 | −8 743 | −9 827 | −164 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 3 961 | 2 476 | 11 638 | 5 681 | 6 874 |
| Equity | 2 657 | −2 561 | 10 634 | 4 998 | 4 834 |
| Long-term debt | 0 | 4 390 | 0 | 0 | 0 |
| Short-term debt | 1 304 | 647 | 1 004 | 683 | 2 040 |
| Total debt | 1 304 | 5 037 | 1 004 | 683 | 2 040 |
EBITDA margin
-74.3%
This company
15.8%
Market median
-570% vs market
20192023
Equity ratio
70.3%
This company
38.2%
Market median
+84% vs market
20192023
Return on equity
-3.4%
This company
18.4%
Market median
-118% vs market
20192023
Net profit margin
-76.6%
This company
8.1%
Market median
-1046% vs market
20192023
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20192023
Debt / equity
0.42×
This company
0.62×
Market median
+32% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AB Liquidator | Liquidator | 2024 |
JE Chief Auditor | Chief Auditor | 2021 |
| Former (1) | ||
ME Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (8) | ||
| Chairman | 2021 – 2022 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2021 – 2024 | |
| Chairman | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Chairman | 2023 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Genagon Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Birgitta Romell Stenmark | Liquidator | 0 companies |
| Moa Elisabet Fransson | Chief Executive Officer | 0 companies |
| Johan Erik Niclas Bergenmo | Chief Auditor | 0 companies |
| Anders Birger Nordström | Chairman | 0 companies |
| Olof Andries Blokzijl | Board of Directors | 0 companies |
| Svein Arild Mathisen | Board of Directors | 0 companies |
| Johan Lars Fredrik Lund | Board of Directors | 0 companies |
| Eric Richard Åhlberg | Board of Directors | 0 companies |
| Björn Johan Niclas Stjernholm | Chairman | 0 companies |
| Karin Agneta von Wachenfeldt | Board of Directors | 0 companies |
| Johan Erik Simon Fredriksson | Chairman | 0 companies |